JP2023518812A - Ｃｏｖｉｄ１９肺炎を治療するための、トシリズマブとレムデシビルとの組み合わせ - Google Patents

Ｃｏｖｉｄ１９肺炎を治療するための、トシリズマブとレムデシビルとの組み合わせ Download PDF

Info

Publication number
JP2023518812A
JP2023518812A JP2022557087A JP2022557087A JP2023518812A JP 2023518812 A JP2023518812 A JP 2023518812A JP 2022557087 A JP2022557087 A JP 2022557087A JP 2022557087 A JP2022557087 A JP 2022557087A JP 2023518812 A JP2023518812 A JP 2023518812A
Authority
JP
Japan
Prior art keywords
pneumonia
dose
antibody
tocilizumab
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022557087A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518812A5 (enExample
Inventor
ミン バオ，
ラリー ウィルス ツァイ，
マーク ダグラス エイスナー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2023518812A publication Critical patent/JP2023518812A/ja
Publication of JP2023518812A5 publication Critical patent/JP2023518812A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2022557087A 2020-03-23 2021-03-19 Ｃｏｖｉｄ１９肺炎を治療するための、トシリズマブとレムデシビルとの組み合わせ Pending JP2023518812A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062993589P 2020-03-23 2020-03-23
US62/993,589 2020-03-23
US202063011889P 2020-04-17 2020-04-17
US63/011,889 2020-04-17
PCT/US2021/023061 WO2021194860A1 (en) 2020-03-23 2021-03-19 Tocilizumab and remdesivir combination therapy for covid-19 pneumonia

Publications (2)

Publication Number Publication Date
JP2023518812A true JP2023518812A (ja) 2023-05-08
JP2023518812A5 JP2023518812A5 (enExample) 2024-03-29

Family

ID=75581614

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022557087A Pending JP2023518812A (ja) 2020-03-23 2021-03-19 Ｃｏｖｉｄ１９肺炎を治療するための、トシリズマブとレムデシビルとの組み合わせ

Country Status (4)

Country Link
US (1) US20230174656A1 (enExample)
EP (1) EP4107186A1 (enExample)
JP (1) JP2023518812A (enExample)
WO (1) WO2021194860A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230192872A1 (en) * 2020-04-01 2023-06-22 The University Of Chicago Tocilizumab for the treatment of viral infections

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
AU668349B2 (en) 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
EP0626012B1 (en) 1992-02-11 2003-07-09 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2003068260A1 (fr) 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
TWI698444B (zh) 2014-10-29 2020-07-11 美商基利科學股份有限公司 製備核糖苷的方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"CllinicalTrial. gov", TOCILIZUMAB IN COVID-19 PNEUMONIA (TOCIVID-19) (TOCIVID-19), JPN6025008800, 19 March 2020 (2020-03-19), ISSN: 0005677619 *
"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon", NATURE COMMUNICATIONS, vol. 11, no. 222, JPN6025008797, 10 January 2020 (2020-01-10), pages 1 - 14, ISSN: 0005677616 *
"Coronavirus puts drug repurposing on the fast track", NATURE BIOTECHNOLOGY, vol. 38, no. 4, JPN6025008799, 27 February 2020 (2020-02-27), pages 379 - 381, ISSN: 0005677618 *
"Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis", CLLINICALTRIAL. GOV, JPN6025008798, 18 March 2020 (2020-03-18), ISSN: 0005677617 *

Also Published As

Publication number Publication date
US20230174656A1 (en) 2023-06-08
WO2021194860A1 (en) 2021-09-30
EP4107186A1 (en) 2022-12-28

Similar Documents

Publication Publication Date Title
WO2021202563A1 (en) Methods of treating coronavirus infection
US20220195065A1 (en) Pharmaceutical formulations and dosage regimens for multi-specific binding proteins that bind her2, nkg2d, and cd16 for cancer treatment
CN115916834A (zh) 帕妥珠单抗加曲妥珠单抗的固定剂量组合
CA3181026A1 (en) Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
AU2019393334A1 (en) Method of treating neutrophilic conditions
US20240287170A1 (en) Methods for treating systemic sclerosis
EP4007640A1 (en) Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
US20240043543A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
US20230125415A1 (en) Biomarkers for predicting response to il-6 antagonist in covid-19 pneumonia
JP2024542777A (ja) 多発血管炎、好酸球増多症候群、好酸球増多症候群、鼻ポリープを伴う慢性副鼻腔炎（ｃｒｓｗｎｐ）又は鼻ポリープを伴わない慢性副鼻腔炎（ｃｒｓｓｎｐ）の処置における使用のためのインターロイキン５結合タンパク質投与レジメン
US20230174656A1 (en) Tocilizumab and remdesivir combination therapy for covid-19 pneumonia
US20230357418A1 (en) Results of empacta: a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of tocilizumab in hospitalized patients with covid-19 pneumonia
JP2023506779A (ja) 慢性移植片対宿主病の処置用抗体
US20240117058A1 (en) Treatment of cytokine release syndrome with gm-csf antagonists
JP2023518815A (ja) Ｉｌ６アンタゴニストによるｃｏｖｉｄ－１９肺炎を含む肺炎の治療方法
CN121548431A (zh) 包含偶联物的药物组合的治疗方法和用途
CN116490520A (zh) 用于covid-19肺炎的托珠单抗和瑞德西韦组合疗法
CN119677533A (zh) 用于治疗癌症的检查点抑制剂与溶瘤病毒的组合
TW202206457A (zh) 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體
US20250333530A1 (en) Combination treatment of glofitamab and chemotherapy
US20260103515A1 (en) DOSES AND PHARMACEUTICAL COMPOSITIONS OF A CD33 x Vd2 BISPECIFIC ANTIBODY FOR THE TREATMENT OF CANCER
WO2025242619A1 (en) Treatment for mucus plugging
WO2021207667A1 (en) Compositions and methods for treating lung injury or acute respiratory distress syndrome (ards)
WO2025108438A1 (zh) 抗her3抗体药物偶联物和抗vegf抗体治疗肿瘤的方法
HK40037896B (en) Subcutaneous her2 antibody formulations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240318

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250311

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250902